July 16, 2024 12:17 PM EDTUpdated 01:07 PM

FDA warns Chinese drugmaker for serious GMP record violations

Zachary Brennan

Senior Editor

The FDA on Tuesday released a warning letter sent to China-based drugmaker Jiangsu Hengrui Pharmaceuticals, finding the company failed at multiple levels to ensure its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA warns Chinese drugmaker for serious GMP record violations

Zachary Brennan

Senior Editor

Sign up to read this article for free.

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Applied Therapeutics' rare disease drug gets a CRL

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

FDA warns Chi­nese drug­mak­er for se­ri­ous GMP record vi­o­la­tions

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA warns Chinese drugmaker for serious GMP record violations

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Applied Therapeutics' rare disease drug gets a CRL

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam